Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
651
datasets available to search
ShareScore release 0.9.0
Dataset results
651 results for “Age-related macular degeneration”
Genetic association analysis of anti-VEGF treatment response in neovascular age-related macular degeneration
<p>Summary statisics of an association study of 6,908,005 genetic variants with anti-VEGF nAMD treatment response in 179 treatment-naïve nAMD probands. This dataset supplements the publication "Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration" (DOI: 10.3390/ijms23116094). Details regarding the methods and version numbers can be found in the corresponding manuscript.</p>
ValRun: GMP-grade Manufacturing and Quality Control of a Non-Virally engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration
<p><strong>VaLRun: </strong></p> <p><strong>Raw data of "GMP-grade Manufacturing and Quality Control of a Non-Virally engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration"</strong></p> <p>(Excel-, pdf-, GraphPad-files, mp4 videos and a READ-ME text file)</p> <p>The introduction of new therapeutics requires validation of Good Manufacturing Practice (GMP)-grade manufacturing including suitable quality controls. This is challenging for Advanced Therapy Medicinal Products (ATMP) with personalized batches. We have developed a person-alized, cell-based gene therapy to treat age-related macular degeneration and established a vali-dation strategy of the GMP-grade manufacture for the ATMP; manufacturing and quality control were challenging due to a low cell number, batch-to-batch variability and short production duration. Instead of patient iris pigment epithelial cells, human donor tissue was used to produce the transfected cell product (“tIPE”). We implemented an extended validation of 104 tIPE productions. Procedure, operators and devices have been validated and qualified by determining cell number, viability, extracellular DNA, sterility, duration, temperature and volume. Transfected autologous cells were transplanted to rabbits verifying feasibility of the treatment. A container has been engineered to insure a safe transport from the production to the surgery site. Criteria for successful validation and qualification were based on tIPE’s Critical Quality Attributes and Process Parameters, its manufacture and release criteria. The validated process and qualified operators are essential to bring the ATMP into clinic and offer a general strategy for the transfer to other manufacture centers and personalized ATMPs.</p>
Data to "Choroidal changes in intermediate age-related macular degeneration patients with drusen or pseudodrusen."
<p>This record contains experimental and analysis scripts (written in Matlab) as well as raw and processed data to reproduce the results shown in:</p> <p>Rosa R., Corazza P., Musolino M., Mochi C., Maiello G., Traverso C. E., & Nicolò M. Choroidal changes in intermediate age-related macular degeneration patients with drusen or pseudodrusen. European Journal of Ophthalmology. (in press)</p> <p> </p>
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
ClinicalTrials.gov study NCT05269966. IPD Sharing: YES. Countries: 1. Publications: 16.
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
ClinicalTrials.gov study NCT04679935. IPD Sharing: YES. Countries: 2. Publications: 1.
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
ClinicalTrials.gov study NCT04264819. IPD Sharing: YES. Countries: 1. Publications: 1.
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01527500. IPD Sharing: YES. Countries: 1. Publications: 1.
Data from: One and two year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource
Objectives: To analyse treatment outcomes and share clinical data from a large, single-center, well-curated database (8174 eyes / 6664 patients with 120,756 single entries) of patients with neovascular age related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (VEGF). By making our depersonalised raw data openly available, we aim to stimulate further research in AMD, as well as setting a precedent for future work in this area. Setting: Retrospective, comparative, non-randomised electronic medical record (EMR) database cohort study of the UK Moorfields AMD database with data extracted between 2008 and 2018. Participants: Including one eye per patient, 3357 eyes/patients (61% female). Extraction criteria were ≥ 1 ranibizumab or aflibercept injection, entry of "AMD" in the diagnosis field of the EMR, and a minimum of one year of follow-up. Exclusion criteria were unknown date of first injection and treatment outside of routine clinical care at Moorfields before the first recorded injection in the database. Main outcome measures: Primary outcome measure was change in VA at one and two years from baseline as measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Secondary outcomes were the number of injections and predictive factors for VA gain. Results: Mean VA gain at one-year and two years were +5.5 (95%CI:5.0,6.0) and +4.9 (95%CI:4.2,5.6) letters respectively. Fifty-four percent of eyes gained ≥5 letters at two years, 63% had stable VA (±≤14 letters), forty-four percent of eyes maintained good VA (≥70 letters). Patients received a mean of 7.7 (95%CI:7.6,7.8) injections during year one and 13.0 (95%CI:12.8,13.2) injections over two years. Younger age, lower baseline VA, and more injections were associated with higher VA gain at two years. Conclusion: This study benchmarks high quality EMR study results of real life AMD treatment and promotes open science in clinical AMD research by making the underlying data publicly available.
Data set for the article titled hypertension affects the treatment of wet age-related macular degeneration
<p>This is concise data set for the article titled Hypertension affects the treatment of wet age-related macular degeneration</p>
Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration
<p>Anonymous dataset from all patients included in the study</p>
Improving Function in Age-Related Macular Degeneration
ClinicalTrials.gov study NCT00572039. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT02484690. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
ClinicalTrials.gov study NCT03525613. IPD Sharing: Not stated. Countries: 14. Publications: 4.
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
ClinicalTrials.gov study NCT02247479. IPD Sharing: Not stated. Countries: 19. Publications: 8.
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
ClinicalTrials.gov study NCT02564978. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT03150589. IPD Sharing: NO. Countries: 9. Publications: 2.
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
ClinicalTrials.gov study NCT04126317. IPD Sharing: YES. Countries: 2. Publications: 1.
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
ClinicalTrials.gov study NCT00423189. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
ClinicalTrials.gov study NCT01782352. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
ClinicalTrials.gov study NCT02087085. IPD Sharing: Not stated. Countries: 6. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.